|
1
|
Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou
ZX and Chen WQ: Nasopharyngeal carcinoma incidence and mortality in
China in 2010. Chin J Cancer. 33:381–387. 2014.PubMed/NCBI
|
|
2
|
Liu MT, Hsieh CY, Chang TH, Lin JP, Huang
CC and Wang AY: Prognostic factors affecting the outcome of
nasopharyngeal carcinoma. Jpn J Clin Oncol. 33:501–508. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liang Z and Xi Y: MicroRNAs mediate
therapeutic and preventive effects of natural agents in breast
cancer. Chin J Nat Med. 14:881–887. 2016.PubMed/NCBI
|
|
4
|
Xing Z, Li D, Yang L, Xi Y and Su X:
MicroRNAs and anticancer drugs. Acta Biochim Biophys Sin
(Shanghai). 46:233–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qin X, Chen J, Wu L and Liu Z: miR-30b-5p
acts as a tumor suppressor, repressing cell proliferation and cell
cycle in human hepatocellular carcinoma. Biomed Pharmacother.
89:742–750. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Wu L and Wu J: Downregulation of
miR-154 in human glioma and its clinicopathological and prognostic
significance. J Int Med Res. 44:994–1001. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tian F, Chen J, Zheng S, Li D, Zhao X,
Jiang P, Li J and Wang S: miR-124 targets GATA6 to suppress
cholangiocarcinoma cell invasion and metastasis. BMC Cancer.
17:1752017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He B, Xu Z, Chen J, Zheng D, Li A and
Zhang LS: Upregulated microRNA-143 inhibits cell proliferation in
human nasopharyngeal carcinoma. Oncol Lett. 12:5023–5028. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao W, Lam JW, Li JZ, Chen SQ, Tsang RK,
Chan JY and Wong TS: MicroRNA-138-5p controls sensitivity of
nasopharyngeal carcinoma to radiation by targeting EIF4EBP1. Oncol
Rep. 37:913–920. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang T, Yin L, Wu J, Gu JJ, Wu JZ, Chen
D, Yu HL, Ding K, Zhang N, Du MY, et al: MicroRNA-19b-3p regulates
nasopharyngeal carcinoma radiosensitivity by targeting
TNFAIP3/NF-kB axis. J Exp Clin Cancer Res. 35:1882016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Lv Z, He G, Wang J, Zhang X, Lu G,
Ren X, Wang F, Zhu X, Ding Y, et al: The SOX17/miR-371-5p/SOX2 axis
inhibits EMT, stem cell properties and metastasis in colorectal
cancer. Oncotarget. 6:9099–9112. 2015.PubMed/NCBI
|
|
13
|
He D, Miao H, Xu Y, Xiong L, Wang Y, Xiang
H, Zhang H and Zhang Z: miR-371-5p facilitates pancreatic cancer
cell proliferation and decreases patient survival. PloS One.
9:e1129302014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu RY, Diao CF, Zhang Y, Wu N, Wan HY,
Nong XY, Liu M and Tang H: miR-371-5p down-regulates pre mRNA
processing factor 4 homolog B (PRPF4B) and facilitates the G1/S
transition in human hepatocellular carcinoma cells. Cancer Lett.
335:351–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Igney FH and Krammer PH: Immune escape of
tumors: Apoptosis resistance and tumor counterattack. J Leukoc
Boil. 71:907–920. 2002.
|
|
16
|
Lessene G, Czabotar PE and Colman PM:
BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov.
7:989–1000. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bajwa N, Liao C and Nikolovska-Coleska Z:
Inhibitors of the anti-apoptotic Bcl-2 proteins: A patent review.
Expert Opin Ther Pat. 22:37–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fendri A, Kontos CK, Khabir A,
Mokdad-Gargouri R, Ardavanis A and Scorilas A: Quantitative
analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: An
unfavorable and independent prognostic factor. Tumour Boil.
31:391–399. 2010. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gomes BC, Rueff J and Rodrigues AS:
MicroRNAs and cancer drug resistance. Methods Mol Biol.
1395:137–162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cory S, Huang DC and Adams JM: The Bcl-2
family: Roles in cell survival and oncogenesis. Oncogene.
22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hockenbery D, Nunez G, Milliman C,
Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial
membrane protein that blocks programmed cell death. Nature.
348:334–336. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi J, Choi K, Benveniste EN, Rho SB,
Hong YS, Lee JH, Kim J and Park K: Bcl-2 promotes invasion and lung
metastasis by inducing matrix metalloproteinase-2. Cancer Res.
65:5554–5560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sheng H, Shao J, Morrow JD, Beauchamp RD
and DuBois RN: Modulation of apoptosis and Bcl-2 expression by
prostaglandin E2 in human colon cancer cells. Cancer Res.
58:362–366. 1998.PubMed/NCBI
|
|
25
|
He CY and Yang J: miR-187 induces
apoptosis of SiHa cervical carcinoma cells by downregulating Bcl-2.
Genet Mol Res. 16:gmr160189692017. View Article : Google Scholar
|
|
26
|
Ma Z, Luo Y and Qiu M: miR-143 Induces the
apoptosis of prostate cancer LNCap cells by suppressing Bcl-2
expression. Med Sci Monit. 23:359–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
